11. Letairis

Gilead's Letairis is losing patent protections this summer. (Image: Gilead China)

Company: Gilead
2017 U.S. sales: $887 million
Disease: Pulmonary arterial hypertension
Patent expiration: July 29

Just as Gilead expects another steep decline in hepatitis C sales this year, it's also anticipating the loss of patent protections for an important, if smaller, contributor: Letairis, a treatment for pulmonary arterial hypertension.

First approved in 2007, the drug brought in $887 million in U.S. sales last year. Its patent life runs out in July, Gilead CFO Robin Washington told analysts on the company’s fourth-quarter earnings call. In a year-end investor presentation, the drugmaker said it expects copycat competition to take a $300 million to $400 million bite out of Letairis sales this year.

That decline comes even as Gilead is forecasting $3.5 billion to $4 billion in hep C sales for 2018, far short of analyst expectations of $5 billion—and way down from peak levels in 2015 and 2016.

RELATED: Gilead's Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back

Gilead is hoping newer meds can help it absorb the Letairis hit and hep C declines, and one drug it's counting on for help is its new HIV launch Biktarvy. Approved in February, the med comes with megablockbuster expectations; peak sales estimates range from $6 billion to $10 billion.

And then there's Gilead's move into CAR-T. After inking its $11.9 billion Kite Pharma buyout last year, it won a second-to-market CAR-T approval for Yescarta in October, trailing Novartis’ Kymriah.

Gilead isn't the only company that stands to suffer from Letairis’ patent loss. Johnson & Johnson's Opsumit—acquired along with Actelion last year—could see sales eroded, too, J.P. Morgan analysts concluded in a research report. “[P]hysician preference data and more favorable coverage already give Letairis an edge” over the J&J drug, the analysts point out. And as history shows, when one drug in a particular field goes generic, other competitors often suffer.

Still, Gilead and J&J could get something of a reprieve. The J.P. Morgan analysts cautioned that Letairis generics could see REMS delays that have held up other copycats.

11. Letairis

Suggested Articles

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.